Rezolute reports interim results from phase 3 tumor hyperinsulinism trial

June 2, 2026 7:00 AM

Rezolute Inc. (NASDAQ: RZLT) reported interim data from its phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with six ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found